FINWIRES · TerminalLIVE
FINWIRES

纳斯达克和标普500指数连续创下历史新高

-- 周四,随着人们对中东冲突有望得到解决的希望日益增强,纳斯达克综合指数和标普500指数均创下新高。 纳斯达克综合指数上涨0.4%,收于24,102.7点;标普500指数上涨0.3%,收于7,041.3点,两大指数均连续第二天创下收盘新高。纳斯达克综合指数的连涨势头已延续至12个交易日。 道琼斯工业平均指数上涨0.2%,收于48,578.7点。 多数板块收涨,能源板块领涨,而医疗保健板块跌幅最大。 美国总统特朗普周四表示,黎巴嫩和以色列已同意停火10天。 特朗普在社交媒体上发文称,他将邀请以色列总理内塔尼亚胡和黎巴嫩总统奥恩前往白宫进行“有意义的会谈”。 “双方都希望实现和平,我相信和平很快就会到来,”他写道。 停火旨在暂停以色列与伊朗支持的黎巴嫩真主党之间的敌对行动,这是美国与德黑兰和平谈判的关键症结所在。 周四下午晚些时候,西德克萨斯中质原油价格上涨2.4%,至每桶93.50美元;布伦特原油价格上涨3.4%,至每桶98.19美元。 “由于市场对霍尔木兹海峡的混乱局面能否很快缓解存在疑虑,油价上涨,”D.A. Davidson在一份报告中表示。 美国国债收益率走高,10年期国债收益率上涨2.6个基点至4.31%,2年期国债收益率上涨1.6个基点至3.79%。 公司新闻方面,IBM(IBM)股价上涨2.5%,成为道琼斯指数中涨幅第三大的股票。奥本海默在一份报告中指出,受软件业务强劲增长以及提前完成对Confluent的收购,这家科技巨头第一季度业绩可能超出华尔街预期,并上调营收预期。IBM计划于下周公布季度业绩。 嘉信理财(SCHW)股价下跌7.6%,为标普500指数成分股中跌幅最大。这家金融服务提供商第一季度业绩同比增长,客户资产激增,但营收低于华尔街预期。 雅培(ABT)紧随嘉信理财之后,在标普500指数中下跌6%。这家医疗保健公司下调了全年盈利预期,以反映对癌症诊断公司Exact Sciences的收购。 百事可乐(PEP)公布的第一财季业绩高于预期,这得益于其推行的降低消费者负担能力的举措。这家饮料和零食公司重申了其全年业绩预期。其股价上涨2.3%。 经济新闻方面,美联储数据显示,美国3月份工业生产意外下滑。 牛津经济研究院在一份报告中指出,现在就将此次下滑归咎于中东冲突还为时过早,此次下滑主要是由于采矿业和公用事业部门的产出“大幅下降”。 黄金价格最新下跌0.2%,至每盎司4813.70美元;白银价格下跌1.2%,至每盎司78.68美元。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB